Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Area of Science:

• Oncology
• Urology

Background:

• Metastatic, castration-sensitive prostate cancer (mCSPC) remains a significant clinical challenge.
• Androgen receptor (AR) signaling is a key driver in prostate cancer progression.
• Current treatment strategies for mCSPC aim to inhibit AR signaling and prolong patient survival.

Purpose of the Study:

• To evaluate the efficacy and safety of apalutamide in combination with androgen-deprivation therapy (ADT) for patients with mCSPC.
• To determine if apalutamide plus ADT improves radiographic progression-free survival (rPFS) and overall survival (OS) compared to placebo plus ADT.

Main Methods:

• A double-blind, phase 3 randomized controlled trial (TITAN) was conducted.
• Patients with mCSPC were assigned to receive either apalutamide (240 mg/day) or placebo, both in conjunction with ADT.
• Primary endpoints included rPFS and OS.

Main Results:

• A total of 1052 patients were randomized (525 to apalutamide, 527 to placebo).
• At 24 months, rPFS was 68.2% with apalutamide vs. 47.5% with placebo (HR 0.48, P<0.001).
• Overall survival at 24 months was 82.4% with apalutamide vs. 73.5% with placebo (HR 0.67, P=0.005).
• Grade 3 or 4 adverse events were similar between groups (42.2% vs. 40.8%), with rash being more frequent in the apalutamide arm.

Conclusions:

• The addition of apalutamide to ADT significantly prolongs both radiographic progression-free survival and overall survival in patients with mCSPC.
• Apalutamide demonstrated a comparable safety profile to placebo when added to ADT.
• These findings support apalutamide as a valuable treatment option for patients with metastatic, castration-sensitive prostate cancer.